Table 2 Number of pathology results of benign and malignant endometrial lesions and its mean values of DW-ADC, DT-FA, and DT-ADC (MD)

Benign pathology

No.

Mean DW-ADC ± SD

Mean DT-FA ± SD

Mean DT-MD ± SD

 Endometrial polyp

2

(9.5%)

1.615 ± 0.05233

0.4595 ± 0.07990

1.4645 ± 0.01768

 Sub-mucous fibroid

2

(9.5%)

1.284 ± 0.13011

0.2665 ± 0.01768

1.4140 ± 0.02121

 Endometrial adhesion

1

(4.8%)

1.452 ± 0.0

0.3020 ± 0.0

1.4210 ± 0.0

 Tamoxifen-induced hyperplasia

6

(28.6%)

1.522 ± 0.16364

0.2878 ± 0.04794

1.4295 ± 0.05386

 Simple hyperplasia without cellular atypia (cystic)

5

(23.8%)

1.651 ± 0.16233

0.2242 ± 0.09106

1.3292 ± 0.03167

 Complex hyperplasia without cellular atypia (adenomatous)

3

(14.3%)

1.629 ± 0.09531

0.3490 ± 0.02464

1.2927 ± 0.01531

 Atypical hyperplasia

2

(9.5%)

1.645 ± 0.22981

0.2365 ± 0.04596

1.1945 ± 0.01768

Total

21

100%

1.562 ± 0.17016

0.2915 ± 0.08694

1.3651 ± 0.08747

Test of significance

P1 = 0.1799

P1 = 0.014*

P1 < 0.001*

Malignant pathology

No.

Mean DW-ADC ± SD

Mean DT-FA ± SD

Mean DT-MD ± SD

 Endometrioid adenocarcinoma G1

8

(40%)

0.9899 ± 0.12611

0.3441 ± 0.05055

0.9658 ± 0.07447

 Endometrioid adenocarcinoma G2

4

(20%)

0.8635 ± 0.06998

0.2620 ± 0.05373

0.7460 ± 0.08465

 Endometrioid adenocarcinoma G3

2

(10%)

0.6985 ± 0.02758

0.4060 ± 0.10889

0.4420 ± 0.04667

 Papillary serous carcinoma

2

(10%)

0.6275 ± 0.05869

0.2355 ± 0.05586

0.4635 ± 0.00778

 Mixed type adenocarcinoma (endometrioid and serous)

2

(10%)

0.7155 ± 0.02051

0.2385 ± 0.06293

0.4155 ± 0.02051

 Clear cell carcinoma

1

(5%)

0.897 ± 0.0

0.1480 ± 0.0

0.4970 ± 0.0

 Endometrial stromal sarcoma

1

(5%)

0.912 ± 0.0

0.2800 ± 0.0

0.4400 ± 0.0

Total

20

0.8633 ± 0.15753

0.2994 ± 0.08230

0.7144 ± 0.24580

Test of significance

P2 = 0.0044*

P2 = 0.018*

P2 < 0.001*